Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardiff OncologyCRDF +5.90%31 Cash Ratio is 3.18 as of Mar. 2026, which is 43% below its 10-year median of 5.62. GuruFocus rates CRDF with a GF Score™ of 31/100. The stock has 4 warning signs investors should review. Among 1,384 Biotechnology companies, Cardiff Oncology ranks better than 52.17% on this metric.
Cardiff Oncology (NAS:CRDF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Cardiff Oncology Cash Ratio Related Terms
Cardiff Oncology Cash Ratio Historical Data
* Premium members only.
The historical data trend for Cardiff Oncology's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cardiff Oncology's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiff Oncology Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Cardiff Oncology's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiff Oncology (CRDF) has a Cash Ratio of 3.18 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Cardiff Oncology and its competitors. This is 43% below median its historical median of 5.62. Over the past decade, Cardiff Oncology's Cash Ratio has ranged from 1.04 to 30.59. According to the industry distribution chart, Cardiff Oncology ranks #662 out of 1384 companies in the Biotechnology industry, placing it in the top 47.8%.
Is Cardiff Oncology's Cash Ratio too high?
Cardiff Oncology's current Cash Ratio of 3.18 is 43% below median its 10-year median of 5.62. Over the past 10 years, this metric has ranged from a low of 1.04 to a high of 30.59. The Biotechnology industry median Cash Ratio is 2.93. Cardiff Oncology's value of 3.18 is 8.5% above this industry median. Based on the distribution chart, Cardiff Oncology ranks #662 out of 1384 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cardiff Oncology has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's Cash Ratio compare to MNOV and PMVP?
According to the Biotechnology industry distribution chart, Cardiff Oncology ranks #662 out of 1384 companies for Cash Ratio. This puts Cardiff Oncology in the upper half of its industry. The industry median Cash Ratio is 2.93. Cardiff Oncology's value of 3.18 is 8.5% above this benchmark. Historically, Cardiff Oncology's own Cash Ratio has ranged from 1.04 to 30.59 over the past decade. While the company's 10-year median is 5.62 vs. the industry median of 2.93, Cardiff Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardiff Oncology's current Cash Ratio of 3.18 is 8.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Cardiff Oncology and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiff Oncology's current Cash Ratio is 3.18, which is 43% below median its own 10-year median of 5.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Cardiff Oncology (CRDF) has a current Cash Ratio of 3.18. The current Cash Ratio is 3.18, which is 43% below median its 10-year median of 5.62 and 8.5% above the Biotechnology industry median of 2.93. Cardiff Oncology's overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current Cash Ratio is 3.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
31GF Score
Get the complete analysis for CRDF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRDF has been successfully added to your 
